KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Payables (2017 - 2026)

Amneal Pharmaceuticals has reported Payables over the past 9 years, most recently at $55.5 million for Q4 2025.

  • For Q4 2025, Payables rose 2774150.0% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $55.5 million, up 2774150.0%, while the annual FY2025 figure was $55.5 million, 2774150.0% up from the prior year.
  • Payables for Q4 2025 was $55.5 million at Amneal Pharmaceuticals, down from $731.8 million in the prior quarter.
  • Over five years, Payables peaked at $731.8 million in Q3 2025 and troughed at $2000.0 in Q4 2024.
  • A 5-year average of $269.4 million and a median of $50.6 million in 2024 define the central range for Payables.
  • On a YoY basis, Payables climbed as much as 2774150.0% in 2025 and fell as far as 100.0% in 2025.
  • Year by year, Payables stood at $525.3 million in 2021, then tumbled by 92.43% to $39.8 million in 2022, then rose by 9.12% to $43.4 million in 2023, then tumbled by 100.0% to $2000.0 in 2024, then soared by 2774150.0% to $55.5 million in 2025.
  • Business Quant data shows Payables for AMRX at $55.5 million in Q4 2025, $731.8 million in Q3 2025, and $1.2 million in Q2 2025.